S. 1542 118th Congress
DRUG Act
Latest action, May 10, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
7 cosponsors
Sponsored by Roger Marshall (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
4 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
7 reports
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
E3 STRATEGIC CONSULTING GROUP
7 reports
7 reports
THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES)
BANNER PUBLIC AFFAIRS, LLC
7 reports
6 reports
6 reports
FRESENIUS KABI USA LLC
WEST FRONT STRATEGIES LLC
5 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
YC CONSULTING, LLC
5 reports
All 25 of 49 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMGEN INC | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| EMD SERONO INC | 7 | $4.7M | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $2.5M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | E3 STRATEGIC CONSULTING GROUP | 7 | $180K | Q4 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $50.1M | Q4 2023 | Q3 2024 | yes | |
| SANOFI US SERVICES INC | 7 | $9.0M | Q4 2023 | Q3 2024 | yes | |
| THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | 7 | $140K | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 7 | $13.5M | Q4 2023 | Q3 2024 | yes | |
| BIOGEN | 6 | $6.2M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 6 | $8.3M | Q4 2023 | Q3 2024 | yes | |
| FRESENIUS KABI USA LLC | WEST FRONT STRATEGIES LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| NATIONAL RURAL LETTER CARRIERS' ASSOCIATION | 5 | $567K | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 5 | $21.8M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | YC CONSULTING, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| AMGEN | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 4 | $1.0M | Q1 2024 | Q3 2024 | yes | |
| EMD SERONO, INC. | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| GENENTECH | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICS | HOOPER, LUNDY & BOOKMAN, P.C. | 4 | $40K | Q4 2023 | Q3 2024 | yes |
| PFIZER INC. | 4 | $8.9M | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| PRIME THERAPEUTICS | 4 | $370K | Q4 2023 | Q3 2024 | yes | |
| PRIME THERAPEUTICS | GOVERNMENT COUNSEL, LLC | 4 | $0 | Q4 2023 | Q3 2024 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $2.9M | Q1 2024 | Q3 2024 | yes |